Suyun Lei1, Lizhu Hong1, Cuixian Yang1, Shuang Zhang2, Yanyun Zhang1, Shizhen Huang1, Ronghui Xie1, Xia Li1, Qing Ma3, Huiqin Li1. 1. a Department of Infectious Diseases , Yunnan Provincial Hospital of Infectious Disease , Kunming , Yunan , China. 2. b Department of Infectious Diseases , Renmin Hospital Hubei University of Medicine , Shiyan , Hubei , China. 3. c School of Pharmacy and Pharmaceutical Sciences , University at Buffalo , Buffalo , NY , USA.
Abstract
Background: The combination of rilpivirine with methadone may result in complex interactions secondary to the induction of oxidative metabolism by rilpivirine. Research design and methods: TMC278IFD4007 was a single-center, prospective, open-label, multiple-dose study with 12 HIV-infected Chinese participants. The objective was to evaluate the potential effect of rilpivirine on the pharmacokinetics of methadone. The participants received a daily dose of 25 mg rilpivirine for 11 days with individualized methadone ranging from 25 to 100 mg. Pharmacokinetic studies of methadone were conducted on day 1 and 11. Opiate withdrawal symptoms were evaluated. Results: A large inter-subject variability was noted in methadone pharmacokinetics. Rilpivirine increased methadone minimum and maximum plasma concentrations (Cmin; Cmax) and area under the plasma concentration-time curve versus methadone alone (least-square mean ratio; 90% confidence interval) by 5% (1.05; 0.46, 2.39), 5% (1.05; 0.73, 1.52), and 6% (0.75; 0.74, 1.50) as measured in S-methadone, and 5% (1.05; 0.50, 2.22), 5% (1.05; 0.74, 1.50), and 5% (1.05; 0.76, 1.46) as measured in R-methadone, respectively. No opioid withdrawal symptoms or methadone dose adjustments were reported. Co-administration was well tolerated without serious adverse effects or discontinuations. Conclusion: Concomitant administration of rilpivirine was unlikely to have significant effects on the pharmacokinetics of methadone.
Background: The combination of rilpivirine with methadone may result in complex interactions secondary to the induction of oxidative metabolism by rilpivirine. Research design and methods: TMC278IFD4007 was a single-center, prospective, open-label, multiple-dose study with 12 HIV-infected Chinese participants. The objective was to evaluate the potential effect of rilpivirine on the pharmacokinetics of methadone. The participants received a daily dose of 25 mg rilpivirine for 11 days with individualized methadone ranging from 25 to 100 mg. Pharmacokinetic studies of methadone were conducted on day 1 and 11. Opiate withdrawal symptoms were evaluated. Results: A large inter-subject variability was noted in methadone pharmacokinetics. Rilpivirine increased methadone minimum and maximum plasma concentrations (Cmin; Cmax) and area under the plasma concentration-time curve versus methadone alone (least-square mean ratio; 90% confidence interval) by 5% (1.05; 0.46, 2.39), 5% (1.05; 0.73, 1.52), and 6% (0.75; 0.74, 1.50) as measured in S-methadone, and 5% (1.05; 0.50, 2.22), 5% (1.05; 0.74, 1.50), and 5% (1.05; 0.76, 1.46) as measured in R-methadone, respectively. No opioid withdrawal symptoms or methadone dose adjustments were reported. Co-administration was well tolerated without serious adverse effects or discontinuations. Conclusion: Concomitant administration of rilpivirine was unlikely to have significant effects on the pharmacokinetics of methadone.
Entities:
Keywords:
HIV; Methadone; drug interactions; rilpivirine
Authors: Julia Hanna; David J R Foster; Amy Salter; Andrew A Somogyi; Jason M White; Felix Bochner Journal: Br J Clin Pharmacol Date: 2005-10 Impact factor: 4.335
Authors: S M Clarke; F M Mulcahy; J Tjia; H E Reynolds; S E Gibbons; M G Barry; D J Back Journal: Br J Clin Pharmacol Date: 2001-03 Impact factor: 4.335
Authors: Qing Ma; Olanrewaju O Okusanya; Patrick F Smith; Robert Dicenzo; Judianne C Slish; Linda M Catanzaro; Alan Forrest; Gene D Morse Journal: Expert Opin Drug Metab Toxicol Date: 2005-10 Impact factor: 4.481